Intest Res.  2020 Apr;18(2):139-140. 10.5217/ir.2019.09192.

Enteral nutrition in the biologic era: learn from yesterday, live for today, hope for tomorrow

Affiliations
  • 1Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Japan


Reference

1. Sood A, Singh A, Sudhakar R, et al. Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience. Intest Res. 2020; 18:184–191.
Article
2. Bounous G, Devroede G, Haddad H, Beaudry R, Perey BJ, Lejeune LP. Use of an elemental diet for intestinal disorders and for the critically ill. Dis Colon Rectum. 1974; 17:157–165.
Article
3. Forbes A, Escher J, Hébuterne X, et al. ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 2017; 36:321–347.
Article
4. Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018; 4–CD000542.
Article
5. Akobeng AK, Zhang D, Gordon M, MacDonald JK. Enteral nutrition for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018; 8–CD005984.
Article
6. Nguyen DL, Palmer LB, Nguyen ET, McClave SA, Martindale RG, Bechtold ML. Specialized enteral nutrition therapy in Crohn’s disease patients on maintenance infliximab therapy: a meta-analysis. Therap Adv Gastroenterol. 2015; 8:168–175.
Article
7. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006; 24:1333–1340.
Article
8. Hirai F, Ishihara H, Yada S, et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults. Dig Dis Sci. 2013; 58:1329–1334.
Article
9. Hisamatsu T, Kunisaki R, Nakamura S, et al. Effect of elemental diet combined with infliximab dose escalation in patients with Crohn’s disease with loss of response to infliximab: CERISIER trial. Intest Res. 2018; 16:494–498.
Article
Full Text Links
  • IR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr